Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALT NYSE:BHVN NASDAQ:IMTX NASDAQ:PGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$3.09+1.6%$3.42$2.56▼$7.73$395.52M0.185.50 million shs2.85 million shsBHVNBiohaven$9.83+0.9%$9.81$7.48▼$22.05$1.47B1.321.83 million shs1.98 million shsIMTXImmatics$11.37+2.1%$10.36$4.15▼$12.41$1.49B1.31369,365 shs376,072 shsPGENPrecigen$4.21+1.4%$3.78$1.26▼$5.47$1.48B1.072.83 million shs4.87 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune0.00%+16.92%-9.79%-37.58%-43.28%BHVNBiohaven0.00%+1.63%+3.80%-16.27%-49.12%IMTXImmatics0.00%+1.36%+5.79%+15.68%+154.05%PGENPrecigen0.00%-0.24%+0.73%-3.26%+208.55%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$3.09+1.6%$3.42$2.56▼$7.73$395.52M0.185.50 million shs2.85 million shsBHVNBiohaven$9.83+0.9%$9.81$7.48▼$22.05$1.47B1.321.83 million shs1.98 million shsIMTXImmatics$11.37+2.1%$10.36$4.15▼$12.41$1.49B1.31369,365 shs376,072 shsPGENPrecigen$4.21+1.4%$3.78$1.26▼$5.47$1.48B1.072.83 million shs4.87 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune0.00%+16.92%-9.79%-37.58%-43.28%BHVNBiohaven0.00%+1.63%+3.80%-16.27%-49.12%IMTXImmatics0.00%+1.36%+5.79%+15.68%+154.05%PGENPrecigen0.00%-0.24%+0.73%-3.26%+208.55%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.50Moderate Buy$18.00482.52% UpsideBHVNBiohaven 2.78Moderate Buy$22.47128.60% UpsideIMTXImmatics 2.67Moderate Buy$19.0067.11% UpsidePGENPrecigen 2.43Hold$9.50125.65% UpsideCurrent Analyst Ratings BreakdownLatest ALT, PGEN, BHVN, and IMTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026BHVNBiohaven Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$23.00 ➝ $22.004/28/2026IMTXImmatics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy4/21/2026PGENPrecigen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/13/2026BHVNBiohaven Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$21.004/2/2026BHVNBiohaven CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $17.003/27/2026ALTAltimmune Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/26/2026PGENPrecigen Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$8.00 ➝ $9.003/26/2026PGENPrecigen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $10.003/18/2026ALTAltimmune Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.003/16/2026ALTAltimmune HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$12.00 ➝ $25.003/16/2026IMTXImmatics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$18.00(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$40K10,050.23N/AN/A$1.99 per share1.55BHVNBiohavenN/AN/AN/AN/A$0.86 per shareN/AIMTXImmatics$54.60M27.92N/AN/A$4.09 per share2.78PGENPrecigen$9.68M155.05N/AN/A$0.06 per share70.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.09M-$1.01N/AN/AN/A-214,860.98%-49.35%-41.65%5/12/2026 (Estimated)BHVNBiohaven-$738.82M-$5.67N/AN/AN/AN/A-866.46%-137.99%5/11/2026 (Estimated)IMTXImmatics-$222.26M-$1.84N/AN/AN/A-411.90%-41.81%-34.72%5/12/2026 (Estimated)PGENPrecigen-$250.64M-$1.34N/A15.04N/A-2,588.21%2,317.96%49.65%5/13/2026 (Estimated)Latest ALT, PGEN, BHVN, and IMTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026PGENPrecigen-$0.03N/AN/AN/A$20.81 millionN/A5/12/2026Q1 2026ALTAltimmune-$0.25N/AN/AN/A$0.00 millionN/A5/12/2026Q1 2026IMTXImmatics-$0.42N/AN/AN/A$9.79 millionN/A5/4/2026Q1 2026BHVNBiohaven-$0.86-$0.88-$0.02-$0.88$0.27 millionN/A3/25/2026Q4 2025PGENPrecigen-$0.10-$0.01+$0.09-$0.01$8.29 million$4.57 million3/5/2026Q4 2025ALTAltimmune-$0.25-$0.2719-$0.0219-$0.27$0.00 million$0.03 million3/5/2026Q4 2025IMTXImmatics-$0.48-$0.34+$0.14-$0.34$12.18 million$23.18 million3/2/2026Q4 2025BHVNBiohaven-$1.22-$1.21+$0.01-$1.21$3.86 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/ABHVNBiohavenN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/APGENPrecigenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmune0.1518.5518.55BHVNBiohaven1.877.413.18IMTXImmaticsN/A11.7211.72PGENPrecigen4.463.092.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%BHVNBiohaven88.78%IMTXImmatics64.41%PGENPrecigen33.51%Insider OwnershipCompanyInsider OwnershipALTAltimmune1.60%BHVNBiohaven13.80%IMTXImmatics3.30%PGENPrecigen47.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune50130.10 million128.02 millionOptionableBHVNBiohaven239150.56 million129.78 millionOptionableIMTXImmatics260134.07 million129.65 millionOptionablePGENPrecigen190356.51 million188.59 millionOptionableALT, PGEN, BHVN, and IMTX HeadlinesRecent News About These CompaniesPrecigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13May 7 at 4:05 PM | prnewswire.comPrecigen (PGEN) to Release Earnings on WednesdayMay 6 at 8:54 AM | marketbeat.comPrecigen (NASDAQ:PGEN) Stock Crosses Below 200 Day Moving Average - Here's WhyMay 5, 2026 | marketbeat.comIs Precigen, Inc. (PGEN) A Good Stock To Buy Now?May 3, 2026 | finance.yahoo.comIs Precigen, Inc. (PGEN) A Good Stock To Buy Now?May 3, 2026 | insidermonkey.comComparing Precigen (NASDAQ:PGEN) & ALX Oncology (NASDAQ:ALXO)May 2, 2026 | americanbankingnews.comAnalysts Set Precigen, Inc. (NASDAQ:PGEN) Price Target at $9.50May 1, 2026 | americanbankingnews.comPrecigen, Inc. (NASDAQ:PGEN) Given Consensus Recommendation of "Hold" by AnalystsApril 26, 2026 | marketbeat.comPrecigen (NASDAQ:PGEN) Trading Up 7.5% - Still a Buy?April 20, 2026 | marketbeat.comIs Precigen Inc. (PGEN) The Best Healthcare Penny Stock to Buy?April 15, 2026 | finance.yahoo.comPrecigen (NASDAQ:PGEN) Trading Down 5.6% - Here's WhyApril 14, 2026 | marketbeat.comWall Street bullish on Precigen (PGEN) as the company transitions to commercial stageApril 12, 2026 | msn.comPrecigen (PGEN) price target increased by 11.76% to 9.69April 9, 2026 | msn.comPrecigen sees Q1 revenue exceeding $18M, consensus $20.8MApril 8, 2026 | finance.yahoo.comPrecigen, Inc: Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 MillionApril 7, 2026 | finanznachrichten.dePrecigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 MillionApril 7, 2026 | finance.yahoo.comPrecigen, Inc. (PGEN) Poised for Growth on Respiratory Papillomatosis Treatment ProspectsApril 6, 2026 | insidermonkey.comPrecigen, Inc. (PGEN) Discusses Launch and Differentiation of PAPZIMEOS Immunotherapy for Adult RRP TranscriptApril 1, 2026 | seekingalpha.comPrecigen to Participate in a Fireside Chat with H.C. Wainwright on March 31March 30, 2026 | prnewswire.comIs It Too Late To Consider Precigen (PGEN) After Its 145% One Year Surge?March 27, 2026 | finance.yahoo.comPrecigen gains after 2025 results on Papzimeos outlookMarch 26, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?By Thomas Hughes | April 29, 2026This 4/20, Wall Street Is Betting on More Than MarijuanaBy Jeffrey Neal Johnson | April 20, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026The $880M Bet to Survive Real Estate's ResetBy Jeffrey Neal Johnson | April 28, 2026A Quiet Outperformer With a Catastrophe CaveatBy Peter Frank | April 14, 2026ALT, PGEN, BHVN, and IMTX Company DescriptionsAltimmune NASDAQ:ALT$3.09 +0.05 (+1.64%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$3.08 -0.01 (-0.49%) As of 05/8/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Biohaven NYSE:BHVN$9.83 +0.09 (+0.90%) Closing price 05/8/2026 03:59 PM EasternExtended Trading$9.72 -0.10 (-1.05%) As of 05/8/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Immatics NASDAQ:IMTX$11.37 +0.23 (+2.06%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$11.37 0.00 (0.00%) As of 05/8/2026 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Precigen NASDAQ:PGEN$4.21 +0.06 (+1.45%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$4.19 -0.02 (-0.55%) As of 05/8/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
